Seelos's Amyotrophic Lateral Sclerosis Candidate, SLS-005 An Orphan Drug In Europe - Seelos Therapeutics Inc COM PAR NEW $0.001 (OTC:SEEL) - Benzinga

Seelos Therapeutics Inc's SEEL Trehalose (SLS-005) has received Orphan Drug Designation for amyotrophic lateral sclerosis (ALS) from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP).
Under the orphan designation, Seelos stands to benefit from several incentives such as protocol assistance, reduced regulatory fees, and market exclusivity.
Price Action: SEEL shares are up 2.9% at $3.17 during the premarket session on the last check Thursday.

SEELSeelos Therapeutics Inc COM PAR NEW $0.001

Edge Rankings

Momentum-

Growth-

Quality-

Value-

Price Trend

Short

Medium

Long

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted In:

Biotech News Penny Stocks Health Care Small Cap FDA General Briefs European Medicines Agency (EMA)multiple sclerosis Orphan Drug Designation

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Benzinga.com on devices